Abstract
Introduction

Breast cancer is the most common malignancy among females in Western countries who have an overall lifetime risk of 10% of developing invasive breast cancer [1]. Radiation therapy is considered a common treatment modality for cancer patients, because of its ability to elicit complex cellular responses in various cancerous cells resulting in inhibition of cell growth or apoptosis
. However, the cellular and molecular mechanisms underlying the response of tumours to radiation therapy have not been thoroughly investigated. [7] . Survivin has been found to be activated in most human cancers, although it is either undetectable or expressed at very low levels in differentiated adult tissues [8] . It is estimated that survivin is up-regulated in around 60-70% of breast cancers and its expression has been associated with significant reduction of apoptosis compared to survivin-negative tumours [8, 9] . Recently, it was suggested that in tumours with high endogenous survivin expression, failure to induce apoptosis may result in resistance to radiation therapy [10] . Moreover, down-regulation of survivin was shown to sensitize human tumour cells to ionizing radiation, as well as cytotoxic drugs, such as etoposide and cisplatin [11, 12] . [6, [13] [14] [15] [16] . [17, 18] . HER receptors are involved in the control of diverse biological processes, such as proliferation, differentiation, migration and apoptosis and HER2 plays an important role in the progression of breast cancer tumorigenesis and metastasis [19] . Overexpression or gene amplification of HER2, which occurs in 20-30% of breast cancers, has been found to predict for a poor clinical outcome and resistance to therapy [20] .
Survivin, a member of the inhibitor of apoptosis (IAP) family, appears to be an important cancer therapeutic target and modulation of its expression and/or function may provide rational approaches for cancer therapeutics [5, 6]. IAPs aberrantly function as apoptosis regulators by directly binding and inhibiting caspases, prolonging thus cell viability and contributing possibly to cancer by facilitating mutations and promoting resistance to therapy
Survivin's aberrant expression in the majority of human tumours is unlikely to occur exclusively as a result of gene amplification, as amplicons of the survivin locus have not been observed. Most likely, regulation of survivin expression occurs at the level of transcription as a consequence of the de-regulation of upstream transcriptional regulators and transcription factors, as c-myc, E2F family members, b-catenin/TCF (T-cell factor), nuclear factor (NF)-B and signal transducer and activator of transcription-3 (STAT3)
Additionally, different features of tumour cells, as HER2 and p53, have been shown to be responsible for survivin's regulation, when cells are treated by irradiation or chemotherapy agents and furthermore survivin's expression has been correlated with HER2/neu gene overexpression
In the present study, we investigated the effect of irradiation on survivin ' [21] . 
Materials and methods
Cell cultures and irradiation
Cell viability
Cell cycle distribution
The cell cycle distribution of irradiated and non-irradiated survivin knocked-down cells was determined by flow cytometry as previously described by us [21] . (Fig. 3A) . Univariate 2-factor ANOVA indicated that both examined factors (silenced HER2 and irradiation) have a significant effect on cell viability, reducing it by 80% 24 hrs after irradiation (F ϭ 3869.5ϾϾ1, P Ͻ 0.05). We then performed survivin knockdown using siRNA against survivin (Fig. 3B demonstrates the efficiency of the procedure) and found that it resulted in significant reduction in cell viability in non-irradiated and in 10 Gy irradiated SK-BR-3 cells, although significantly lower than the reduction observed after HER2 knockdown (Fig. 3C) . ANOVA (Fig. 3D) (Fig. 4 
Statistical analysis
), whereas p53 was found to bind p21 promoter in all cell lines except BT-474 (data not shown). Regarding the myc/mad/max protein network, we found a strong binding of both c-myc and mad1 in non-irradiated cells. Max protein was found to bind to survivin promoter in all cells and under all conditions. Irradiated HER2 -MCF-7, MDA-MB-231 and
Fig. 1 Survivin mRNA and protein expression was evaluated by real time PCR and Western blotting in non-irradiated and irradiated breast cancer cell lines respectively. Histograms represent the fold increase or decrease of survivin mRNA expression in irradiated cells, compared to non-irradiated cells. The normalized survivin mRNA expression of non-irradiated cells was set to 1 (*P Ͻ 0.05).
HBL100 cells (with down-regulated survivin) showed no c-myc binding, although mad1 binding was observed. In HER2 overexpressing SK-BR-3 and BT-474 irradiated cells (with up-regulated survivin), the mad1 binding became undetectable at 48 and 72 hrs, respectively. MCF-7/HER2 cells demonstrated signals for all precipitations for non-irradiated and irradiated cells up to 96 hrs, although a weaker signal was observed for c-myc in nonirradiated cells and for mad1 in irradiated cells (especially at 96 hrs after irradiation). Concerning histone acetylation status, we found that acetylated histone H3 signal was increased in irradiated HER2
Study of the occupancy of c-myc promoter by NF-B, downstream target of HER2
Fig. 2 Effect of HER2 expression in the regulation of survivin mRNA expression levels. (A) A total of 40 g of protein from non-irradiated, 10 and 20 Gy irradiated cells were subjected to Western blot analysis of HER2 protein. Analysis for ␤-actin was performed to show equal loading. For simplicity reasons, only 48 hr blots are represented here (72 hrs for MCF-7/HER2 cells). (B) Effect of HER2 knockdown on HER2 and survivin mRNA expression levels. (Bars: standard errors; *P Ͻ 0.05). (C) Effect of HER2 knockdown on HER2 and survivin proteins, as demonstrated by Western blot analysis.
significant relationship between survivin expression and HER2 overexpression in primary breast tumours [17, 18] [25, 26] .
In continuation, we were interested to investigate the activity of survivin's promoter upon irradiation in breast cancer cells.
Survivin's promoter contains a response element for proteins of the myc/mad/max complex, whereas survivin's overexpression in tumours has been linked to loss of wild-type p53 [6, 27] . It has been suggested that survivin may belong to a group of genes targeted for transcriptional repression by p53, providing thus a supplementary mechanism by which p53 exerts its important role in tumour suppression [27, 28] 
